Servings: Conveniently , 90 Servings (90 Tablets)
Retatrutide + MOTS-c vs Cagrilintide + Retatrutide vs Advanced Recomp Stack How the retatrutide + MOTS-c stack compares Feature Components Retatrutide + MOTS-c Retatrutide + MOTS-c Cagrilintide + Retatrutide Retatrutide + Cagrilintide Advanced Recomp Stack Reta or tirz + tesamorelin or CJC/Ipa + MOTS-c (3+) Feature Pathway coverage Retatrutide + MOTS-c Triple agonist + AMPK / mitochondrial Cagrilintide + Retatrutide Triple agonist + amylin (extra satiety) Advanced Recomp Stack Triple agonist + GH axis + AMPK Feature Lean mass focus Retatrutide + MOTS-c Moderate (MOTS-c myostatin signal) Cagrilintide + Retatrutide Low (no dedicated lean-mass mechanism) Advanced Recomp Stack High (dedicated GH secretagogue) Feature Mitochondrial focus Retatrutide + MOTS-c High (MOTS-c is mitochondrial-derived) Cagrilintide + Retatrutide None Advanced Recomp Stack High (MOTS-c usually included) Feature Injections per week Retatrutide + MOTS-c 2 compounds, 4-5 injections Cagrilintide + Retatrutide 2 compounds, 2 injections Advanced Recomp Stack 3+ compounds, 7+ injections Feature Cost (research-grade, monthly) Retatrutide + MOTS-c Moderate ($150-$300 combined) Cagrilintide + Retatrutide Moderate ($200-$400 combined) Advanced Recomp Stack High ($350-$600+ combined) Cost ranges reflect typical research-grade pricing across COA-verified suppliers as of June 2026 - verify supplier pricing before ordering
GHK-Cu and Infection-Related Readouts in Wound Contexts Mouse and clinical datasets point to a possible reduction in inflammatory proteases (for example, MMP-2/9) and cytokines (such as TNF-) in wounds exposed to GHK-Cu, aligning with lower observed infection rates in comparative ulcer care cohorts
10 Pdcd4 has been demonstrated to inhibit tumor promotion and progression, 13 whose expression is often downregulated in colorectal cancer
Unlike thiazolidinediones (such as pioglitazone), which activate peroxisome proliferator-activated receptors and directly promote sodium and water retention, tirzepatide's receptor targets do not have this established effect
